drugset / Trial / NCT00832221

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

NCT00832221

Phase 1 Completed 10 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.

Timeline

Start
2009-01
Primary completion
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 300 mg Oral

Indications